Tryptamine Therapeutics (ASX:TYP) received approval from the Swinburne University Human Research Ethics Committee to initiate an open-label study to assess the safety and efficacy of TRP-8803 in combination with psychotherapy in adult patients with binge eating disorder, according to a Monday filing with the Australian bourse.
The main goal of the trial is to determine the safety and effectiveness of two TRP-8803 doses over a 12-week follow-up period after the second dose.
TRP-8803 is a psilocin-based intravenous-infusion formulation with potential neuroplastic benefits, the filing said.
The trial will administer two doses of TRP-8803 to 12 participants in two patient cohorts, 14 days apart.
Secondary and exploratory objectives include assessing TRP-8803's ability to induce a psychedelic state and its impact on binge-eating frequency and other weight-related measures at both four and 12 weeks post-second dosing, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.